Narayana Hrudayalaya Ltd

- Currently, there are no plans to raise equity capital. - The company does not see a need for equity raising at this time. - For the UK acquisition, debt of GBP 150 million was taken with a 2-year moratorium followed by 5 years of equal principal and interest repayments. - Future capital expenditure of around INR 3000 crore will be funded through internal accruals and debt. - The group tracks net debt to EBITDA ratio and aims to maintain it below 2.5. - No immediate plans for international acquisitions or fundraising are indicated; focus remains on optimizing existing operations, especially in the UK and India.

- India CapEx: Planned INR 1000 crore (internal accruals and debt funding); actual closer to INR 3000 crore for expansion, mainly in Bangalore, Kolkata, and Raipur clusters (Page 12, 14, 25). - Addition of four DaVinci robotic surgery systems across hospitals in India next year for advanced surgical capabilities (Page 23). - Minor equipment and sterilization units CapEx in Birmingham (UK) has mostly been completed; no major remaining CapEx (Page 17). - Investment in oncology joint ventures in India: Everhope Oncology (chemo centers in Delhi/Gurgaon) and SSO Oncology in Mumbai with plans to expand; no earmarked further investments yet pending business trajectory (Page 25). - UK acquisition is an asset-light leveraged buyout; no significant immediate CapEx detailed for UK but strategic operational improvements ongoing (Page 26, 15).

- India business: Expected to sustain double-digit like-to-like hospital revenue growth till new hospitals commission (Page 12). - Oncology and cardiac: Projected to account for more than half of revenue going forward, with oncology potentially increasing by 20% (Page 9). - Expansion focus: Consolidating core markets like Bangalore and Kolkata, with investments in new flagship facilities (Page 14). - UK operations: Growth expected through improving performance and expanding private market share, though margins will differ from other markets (Page 15). - Cayman operations: Expected to sustain revenue levels (Page 14). - Clinics and insurance businesses: Still building stage; growth driven by customer acquisition and gradual scaling, with margin dilution expected temporarily (Page 4). - Overall: Revenue and EBITDA growth expected in India and UK; Cayman to sustain current performance (Page 14).

- India business is expected to sustain double-digit revenue growth with continued margin expansion driven by transformation programs and payor mix optimization initiatives. - The UK business (Practice Plus) is anticipated to grow, with Birmingham losses reducing over time. Medium-term ROCE impact expected to normalize and not be dilutive to group ROCE. - Cayman business expected to sustain current levels without significant CapEx plans. - Overall EBITDA is expected to grow in India and UK; Cayman level sustained—this direction suggests PAT growth following a similar upward trend. - Interest costs will increase due to acquisition-related borrowing, impacting PAT but manageable within growth plans. - No explicit numerical guidance provided but emphasis on healthy profitability and cash flow management. - Investment in new ventures like oncology chemo centers will be cautious, based on scaling trajectory, indicating measured capital deployment.

The transcript provided does not mention any details regarding the current or expected order book or pending orders. There is no specific information on order backlog, pending contracts, or order inflow in the document from the earnings call transcript for the quarter ended December 31, 2025. The discussion primarily focuses on operational performance, financials, geographic expansion, business segments, and strategic initiatives across India, UK, and Cayman markets. If you need details specific to orderbook or pending orders, it may require looking at other financial disclosures or reports not included here.